Dr. Matthew I. Milowsky

Dr. Matthew I. Milowsky, MD, FASCO, is a noted medical oncologist specializing in genitourinary malignancies, with a focus on bladder cancer. He serves as the George Gabriel and Frances Gable Villere Distinguished Professor of Medicine at the University of North Carolina School of Medicine, Chief of the Genitourinary Oncology Section, Co-Director of the Urologic Oncology Program, and Co-Leader of the Clinical Research Program at the UNC Lineberger Comprehensive Cancer Center. Dr. Milowsky earned his medical degree from SUNY Downstate, completed his residency in internal medicine at Tufts/New England Medical Center, and pursued fellowship training in hematology and oncology at NewYork-Presbyterian/Weill Cornell. He is board-certified in Medical Oncology and is widely recognized for his leadership in clinical trials and translational research in bladder cancer.

Dr. Milowsky’s research is dedicated to advancing therapies for urothelial and other genitourinary cancers through genomics-driven approaches and immunotherapy. He has led and contributed to national and international clinical trials testing novel agents in bladder and kidney cancers. He is principal investigator for multi-center initiatives such as the Bladder Cancer Advocacy Network’s UC-GENOME project and has chaired the BCAN Bladder Cancer Genomics Consortium. His publications have influenced practice guidelines and expanded therapeutic options for patients with advanced urothelial malignancies.

In addition to his clinical and research achievements, Dr. Milowsky is a trusted educator and mentor. He has trained numerous fellows and junior investigators in genitourinary oncology and is recognized for his collaborative leadership style. He serves on cooperative group committees and advisory boards that help define national standards for bladder and kidney cancer care. Through his dedication to clinical innovation, mentorship, and translational research, Dr. Matthew Milowsky continues to advance the field of genitourinary oncology and improve outcomes for patients with bladder cancer.